San Diego, California–(Newsfile Corp. – February 2, 2022) – Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. (“Anavex Life Sciences” or “the Company”) (NASDAQ: AVXL).
On February 1, 2022, Anavex Life Sciences announced a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following this news, a Senior Writer at Statnews stated, “Anavex changed the primary and secondary endpoints of this Rett study on January 18, allowing it to claim success when the drug most likely failed. This press release is entirely misleading.”
Following this news, Anavex Life Sciences stock closed down 15.6% on February 1, 2022.
If you have information that could assist in this investigation, or if you are an Anavex Life Sciences shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.
To join this action, you can go to:
https://www.cognitoforms.com/JohnsonFistel/AnavexLifeSciencesCorp
or
[Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]
To join this action, you can go to:
https://www.cognitoforms.com/JohnsonFistel/AnavexLifeSciencesCorp
or
[Click here to join this action]. There is no cost or obligation to you.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112531